Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 5, 2011, Pages 557-567

  Lai, P S M ^a   Chua, S S ^a   Chew, Y Y ^b   Chan, S P ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

adherence; bone turnover markers; osteoporosis; persistence; pharmaceutical care; postmenopausal women

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; FEMALE; FRAGILITY FRACTURE; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; PAIN; PATIENT COMPLIANCE; PATIENT COUNSELING; PHARMACEUTICAL CARE; PHARMACIST; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ALENDRONATE; BIOMARKERS, PHARMACOLOGICAL; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HIP; HUMANS; MEDICATION ADHERENCE; MENOPAUSE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PHARMACEUTICAL SERVICES; POSTMENOPAUSE; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052864476     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01210.x     Document Type: Article

References (43)

1. Cranney A, Guyatt G, Griffith L, (2002) IX Summary of meta analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews, 23, 570-578. (Pubitemid 34925651)
2. Pols HAP, Felsenberg D, Hanley DA, et al. (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporosis International, 9, 461-468. (Pubitemid 29231740)
3. Harris ST, Watts N, Genant HK, et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA, 282, 1344-1352. (Pubitemid 29483192)
4. Weycker D, Macarios D, Edelsberg J, Oster G, (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis International, 17, 1645-1652. (Pubitemid 44477625)
5. Lappe J, (2006) Nonadherence to osteoporosis medications: a critical problem. Clinical Reviews in Bone and Mineral Metabolism, 4, 25-32. (Pubitemid 43780271)
6. Siris E, Harris S, Rosen C, et al. (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proceedings, 81, 1013-1022. (Pubitemid 44175011)
7. Sebaldt RJ, Shane LG, Pham B, Cook R, Thabane L, Petrie A, (2004) Long-term effectiveness outcomes of non-compliance and non-persistence with daily regimen bisphoshonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporosis International, 15, [Abstract P391SA].
8. Tosteston AN, Grove MR, Hammond CS, et al. (2003) Early discontinuation of treatment for osteoporosis. American Journal of Medicine, 15, 209-216. (Pubitemid 37338146)
9. Eastell R, Garnero P, Vrijens L, Van de Langerijt L, Pols HAP, Ringe JD, (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcified Tissue International, 72, [Abstract P297].
10. Nielsen D, Ryg J, Nissen N, Nielsen W, Knold B, Brixen K, (2008) Multidisciplinary patient education in groups increases knowledge on osteoporosis: a randomized controlled trial. Scandinavian Journal of Public Health, 36, 346-352. (Pubitemid 351796237)
11. Lai P, Chua SS, Chan SP, (2010) A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis. Osteoporosis International, doi.
12. Clowes JA, Peel NFA, Eastell R, (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism, 89, 1117-1123. (Pubitemid 38368399)
13. Delmas PD, Vrijens B, Eastell R, et al. (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. Journal of Clinical Endrocrinology and Metabolism, 92, 1296-1304. (Pubitemid 46556401)
14. Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X, (2006) Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporosis International, 17, 664-671.
15. Schousboe JT, DeBold RC, Kuno LS, Weiss TW, Chen YT, Abbott TA, (2005) Education and phone follow-up in postmenopausal women at risk for osteoporosis-effects on calcium intake, exercise frequency, and medication use. Disease Management and Health Outcomes, 13, 395-404. (Pubitemid 41783777)
16. Hepler CD, Strand LM, (1990) Opportunities and responsibilities in pharmaceutical care. American Journal of Hospital Pharmacy, 47, 533-543. (Pubitemid 20138134)
17. Jaglal SB, Hawker G, Bansod V, et al. (2009) A demonstration project of a multi-component educational intervention to improve integrated post-fracture osteoporosis care in five rural communities in Ontario, Canada. Osteoporosis International, 20, 265-274.
18. MacLaughlin EJ, MacLaughlin AA, Snella KA, Winston TS, Fike DS, Raehl CR, (2005) Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy, 25, 379-386. (Pubitemid 40300325)
19. Keely JL, (2002) Pharmacist scope of practice. Annals of Int Medicine, 136, 79-85. (Pubitemid 34038700)
20. Delmas PD, (2000b) Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporosis International, 11 (Suppl. 6), S66-S76. (Pubitemid 32039514)
21. Reginster JY, Henrotin Y, Christiansen C, (2001) Bone resorption in post menopausal women with normal and low BMD assessed with biochemical markers specific for telepeptide derived degradation products of collagen type 1. Calcified Tissue International, 69, 130-137. (Pubitemid 32912230)
22. Delmas PD, (2004) Advances in osteoporosis research using biochemical markers of bone turnover. 22nd Annual meeting of the American Society for Bone and Mineral Research, 22-24 (abstract).
23. Pharmacy Information System (2005) Data on file from the University Malaya Medical Centre, using Ascribe version 8.6. Bolton: Pharmacy Information System.
24. Dupont WD, Plummer WD, (2004) PS: power and sample size calculation. Available at:. (accessed 30 June 2007).
25. International Osteoporosis Foundation (2006) Staying power: closing the adherence gap in osteoporosis. Available at:. (accessed 22 August 2008).
26. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB, (2004) The concordance of self-report with other measures of medication adherence: a summary of the literature. Medical Care, 42, 649-652.
27. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R, (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone, 30, 886-890. (Pubitemid 34616018)
28. Abramson JH, Abramson ZH, (1999) Survey methods in community medicine, 5th edn. Edinburgh: Churchill Livingstone.
29. Roughead EE, Semple SJ, Vitry AI, (2005) Pharmaceutical care services: a systematic review of published studies, 1990 to 2003, examining effectiveness in improving patient outcomes. International Journal of Pharmacy and Practice, 13, 53-70. (Pubitemid 40314147)
30. Donner A, Klar N, (2000) Design and analysis of cluster randomization trials in health design. London: John Wiley & Sons, 128-138.
31. Delmas PD, Eastell R, Garnero P, (2000) The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis International, 11, S2-S17. (Pubitemid 32039509)
32. UMMC Medical Records Department (2005) Data on file: number of osteoporosis patients who attended the outpatient clinics in the University Malaya Medical Center. Kuala Lumpur: Medical Records Department of the University Malaya Medical Center.
33. Fosamax. (1999) Product Information (alendronic acid). Whitehouse Station: Merck & Co., Inc.
34. Downey T, Foltz S, Boccuzzi S, Omar M, Kahler K, (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. Southern Medicine Journal, 99, 570-575. (Pubitemid 43999919)
35. Schnitzer T, Bone HG, Crepaldi G, et al. (2000) Therapeutic equivalence of alendronate 70mg once weekly and alendronate 10mg daily in the treatment of osteoporosis. Aging (Milano), 12, 1-12. (Pubitemid 30136655)
36. McDonald HP, Garg AX, Haynes RB, (2002) Interventions to enhance patient adherence to medication prescriptions. JAMA, 288, 2868-2879. (Pubitemid 35425073)
37. Clifford RM, Davis WA, Batty KT, Davis T, (2005) Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care, 28, 771-776. (Pubitemid 40434471)
38. Haynes RB, McDonald HP, Garg AX, (2002) Helping patients follow prescribed treatment-clinical applications. JAMA, 288, 2880-2883. (Pubitemid 35425074)
39. Rizzoli R, (2007) What factors determine patient adherence to osteoporosis treatment regimens? Nature Clinical Practice. Endocrinology Metabolism, 3, 80-81. (Pubitemid 46146956)
40. Papaioannou A, Kennedy C, Dolovich L, Lau E, Adachi J, (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies [Review]. Drugs and Aging, 24, 37-55. (Pubitemid 46148080)
41. Solomon D, Avorn J, Katz J, et al. (2005) Compliance with osteoporosis medications. Archives of Internal Medicine, 15, 2414-2419. (Pubitemid 41640855)
42. Watts N, Freedholm D, Daifotis A, (1999) The clinical tolerability of alendronate. International Journal of Clinical Practice, 101, 51-61.
43. Tanko LB, Mouritzen U, Lehman HJ, et al. (2003) Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone, 32, 687-693. (Pubitemid 37297391)